Sign in
Taking peopleNo phase

Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

Key facts

Who runs it
General Hospital of Shenyang Military Region
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
60 people, planned
Started
2 Jan 2026
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Evolocumab 140 MG/ML [Repatha]
  • Conventional lipid-lowering therapy
Record updated
25 September 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Age 18~75 years
  • Patients with HTG-AP
  • Mixed hyperlipidemia
  • Sign the informed consent form

Who cannot take part

  • Patients who have received lipid-lowering drugs or blood purification treatment within one week before enrollment
  • Patients who have used evolocumab within one month before enrollment
  • Patients who have participated in the clinical research of other drugs within one month
  • Patients who are accompanied by diseases that can seriously affect the survival
  • Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies
  • Patients who are pregnant or breastfeeding
  • Other circumstances that researchers consider not suitable for participation in this study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Hypertriglyceridemia induced acute pancreatitis

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The severity of hypertriglyceridemia induced acute pancreatitis (HTG-AP) is closely related to the serum triglyceride (TG) levels. The higher the TG levels, the greater the risk of developing severe acute pancreatitis (SAP). Previous expert consensus has pointed out that the key to treating HTG-AP is to rapidly lower serum TG levels to below 5.65 mmol/L. Evolocumab is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, which is often used to treat familial hypercholesterolemia, mixed dyslipidemia and atherosclerotic cardiovascular disease. At the same time, evolocumab also has the effect of reducing TG and may provide a feasible option for the management of HTG-AP. However, its efficacy and safety in reducing TG in patients with HTG-AP remain controversial. This study is a multicenter randomized controlled trial to evaluate the efficacy and safety of adding evolocumab to conventional lipid-lowering therapy in patients with HTG-AP.

The 2 groups in the trial

  • Conventional lipid-lowering therapy + Evolocumab groupTreatment being tested

    Treatment: Evolocumab 140 MG/ML [Repatha]

  • Conventional lipid-lowering therapy groupExisting treatment, for comparison

    Treatment: Conventional lipid-lowering therapy

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis: A Pilot Randomised Controlled Trial
Criteria questions
Built from NCT07388420, who can take part
Record updated
25 September 2026